ROCK2 and metabolic dysfunction-associated steatohepatitis: By acting on immune, fibrotic, and metabolic pathways, in addition to targeting distinct cell types, the novel and highly selective ROCK2 inhibitor, GV101, tackles the disease on numerous different angles and turns out to be a very promising therapeutic approach for patients with liver fibrosis due to NASH, as well as for other diseases that progress on inflammatory, metabolic, and fibrotic grounds.